4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Mirxes Holding Company Limited (2629) operates in the Biotechnology industry and is headquartered in Singapore, Singapore with about 347 employees. Its market capitalization is roughly $4 billion. In the fiscal year ended 2024-12-31, 2629 reported $20M in revenue and ($92M) in net income.
Mirxes Holding Company Limited, a micro ribonucleic acid technology company, provides diagnostic solutions for the screening of cancer, cardiovascular, metabolic, and infectious diseases accessible across Singapore and China.
Interactive charts & full statements →
| Income statement | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Revenue | $20M | $24M | $18M |
| Gross Profit | $9M | $14M | $9M |
| Operating Income (EBIT) | ($67M) | ($54M) | ($48M) |
| Net Income | ($92M) | ($69M) | ($57M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|
| Total Assets | $71M | $108M | $120M |
| Total Liabilities | $270M | $240M | $182M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2629 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms